Description: The 6.7 monoclonal antibody reacts with human and non-human primate (rhesus or cynomologus) CD18, which is also known as beta2 integrin. CD18 is a 90-95 kDa type I transmembrane protein that heterodimerizes with the a chain of CD11a, CD11b and CD11c. The CD18/CD11a complex is also known as lymphocyte function-associated antigen-1 (LFA-1) and plays an important role in cellular adhesion and inflammatory reactions. CD18 is expressed broadly by human lymphocytes and monocytes. Peripheral blood granulocytes also express CD18, but at lower levels.
The 6.7 monoclonal antibody has been reported to induce the proliferation of resting T cells cultured with monocytes.
Applications Reported: This 6.7 antibody has been reported for use in flow cytometric analysis.
Applications Tested: This 6.7 antibody has been pre-titrated and tested by flow cytometric analysis of normal human blood cells. This can be used at 5 µL (0.5 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.
Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser.
Filtration: 0.2 µm post-manufacturing filtered.
CD18 integrin beta 2 subunit is a 90 kDa type I transmembrane protein expressed on all leucocytes. CD18 can combine with integrin molecules CD11a-c to form heterodimers at the cell surface, and these heterodimers are known to participate in the process of cell adhesion as well as cell-surface mediated signaling. CD18 forms heterodimers with four types of CD11 molecule to constitute leukocyte (beta2) integrins: alphaLbeta2 (CD11a/CD18, LFA-1), alphaMbeta2 (CD11b/CD18, Mac-1, CR3), alphaXbeta2 (CD11c/CD18) and alphaDbeta2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits, and these integrins are essential for proper leukocyte migration, mediating intercellular contacts. Absence of CD18 leads to leukocyte adhesion deficiency-1, severe reduction of CD18 expression leads to the development of a psoriasiform skin disease. CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis. Defects in the CD18 gene are the cause of leukocyte adhesion deficiency type I (LAD1). Two transcript variants encoding the CD18 protein have been identified.
蛋白别名: CD18; cell surface adhesion glycoprotein (LFA-1/CR3/P150,959 beta subunit precursor); Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; complement component 3 receptor 3 and 4 subunit; complement receptor C3 beta-subunit; Complement receptor C3 subunit beta; integrin beta chain, beta 2; Integrin beta-2; integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); leukocyte cell adhesion molecule CD18; leukocyte-associated antigens CD18/11A, CD18/11B, CD18/11C
基因别名: CD18; ITGB2; LAD; LCAMB; LFA-1; MAC-1; MF17; MFI7
UniProt ID: (Human) Q9UD72
Entrez Gene ID: (Human) 3689